Making large liver tumors removable with immunotherapy and focused radiation
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of immunotherapy and high-precision radiation (SBRT) to shrink large or multiple liver tumors in people with hepatocellular carcinoma, with the goal of making them small enough for surgery. It's for people who cannot currently have their tumors removed but might become eligible after treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have liver cancer (hepatocellular carcinoma) confirmed by standard imaging or biopsy.
- Your main tumor is between 5 and 25 cm, or you have up to 3 tumors, or the tumor involves a branch of the portal vein.
- You are 18 to 80 years old.
- Your liver function is good enough (Child-Pugh class A to B7) and you have a good overall health status (ECOG 0 or 1).
- You have not had cancer in another part of your body, previous radiation to the liver, or tumors that have spread beyond the liver.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new combination for liver cancer that has not responded to one earlier treatment. It uses a focused type of radiation (SBRT) plus an immunotherapy drug called QL1706 (a medicine that helps your immune system attack cancer). The goal is to see if this combination can control the cancer better.
This Phase 1 trial tests how well a combination treatment works for liver cancer that cannot be removed with surgery or other local treatments. It combines two immune/targeted medicines with a focused type of radiation (SBRT) to control the tumors.
This Phase 2 trial studies whether a combination of SBRT (focused radiation) plus tislelizumab and regorafenib can control unresectable or limited-spread liver cancer. It may help by attacking tumors in the liver and immune system to improve shrinkage and control of disease.
This trial tests a combination of targeted radiation (SBRT) and immunotherapy for people with small liver cancers that have come back or are still present after prior treatment. It aims to see if this approach can better control the cancer without using heavy chemotherapy.
This trial tests whether a targeted radiation therapy (SBRT) can help people with liver cancer whose disease has only a few new spots growing while on first-line immunotherapy. It aims to see if zapping those spots can control the cancer and delay the need for stronger treatments.
This trial tests a combination of three treatments—radiation therapy (SBRT), an immunotherapy drug (camrelizumab), and a targeted therapy (apatinib)—to see if they can shrink liver cancer enough to make surgery possible. It is for people whose liver cancer cannot be removed right now.
Hear when a new Unresectable Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.